RTP Mobile Logo
What Urologists Want To Know: Addressing Current Questions and Controversies in the Management of Bladder Cancer (Webinar Audio Proceedings)
Released December 2021

Featuring perspectives from Drs Arjun Balar, Ashish Kamat, Guru Sonpavde and Robert Svatek. Published December 1, 2021. (Webinar Audio Proceedings)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of bladder cancer.

    LEARNING OBJECTIVES

    • Consider the recent FDA approval of pembrolizumab for high-risk non-muscle-invasive urothelial bladder cancer (UBC) that is unresponsive to bacillus Calmette-Guérin immunotherapy, and determine how this agent can be appropriately integrated into current care.
    • Appraise the recent FDA approval of nivolumab as adjuvant treatment for patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection.
    • Evaluate available data and ongoing studies investigating anti-PD-1/PD-L1 antibodies as neoadjuvant therapy, and consider the current and potential role of this treatment strategy.
    • Identify patients appropriate for consideration of anti-PD-1/PD-L1 antibodies in combination with platinum-based chemotherapy for previously untreated metastatic UBC.
    • Review published clinical trial data leading to the FDA approval of the anti-PD-L1 antibody avelumab as maintenance therapy after response to first-line platinum-based chemotherapy for patients with metastatic UBC, and incorporate this novel approach into management algorithms.
    • Recognize the FDA approval of erdafitinib for patients with advanced UBC and susceptible FGFR3 or FGFR2 genetic alterations whose disease has progressed during or after at least 1 line of platinum-containing chemotherapy, and determine how this agent may be appropriately integrated into clinical practice.
    • Recall pivotal clinical trial findings with enfortumab vedotin for previously treated locally advanced or metastatic UBC, and identify patients for whom treatment with this novel compound would be appropriate.
    • Consider how sacituzumab govitecan may be incorporated into the treatment algorithm on the basis of its recent FDA approval for patients with locally advanced or metastatic urothelial cancer who previously received a platinum-containing chemotherapy and an anti-PD-1/PD-L1 antibody.
    • Appraise available research data and ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies in combination with targeted agents or other immunotherapeutic strategies for metastatic UBC, and counsel appropriately selected patients about participation in active research protocols.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 2.25 (audio) and 1.75 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/AUA2021/Bladder/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/AUA2021/Bladder/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/AUA2021/Bladder/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/AUA2021/Bladder.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Arjun Balar, MD
    Associate Professor, Department of Medicine
    Director, Genitourinary Medical Oncology Program
    Medical Director, Clinical Trials Office
    NYU Perlmutter Cancer Center
    New York, New York

    Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Pfizer Inc, Seagen Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Pfizer Inc, Seagen Inc; Ownership Interest: GT Biopharma Inc.

    Ashish M Kamat, MD, MBBS
    Professor of Urologic Oncology (Surgery)
    Wayne B Duddlesten Professor of Cancer Research
    Department of Urology, Division of Surgery
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    No relevant conflicts of interest to disclose.

    Guru Sonpavde, MD
    Bladder Cancer Director
    Dana-Farber Cancer Institute
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: Astellas, AstraZeneca Pharmaceuticals LP, Bicycle Therapeutics, Bristol-Myers Squibb Company, EMD Serono Inc, Exelixis Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Pfizer Inc, Sanofi Genzyme, Scholar Rock, Seagen Inc; Consulting Agreements (Paid): AstraZeneca Pharmaceuticals LP, Debiopharm, EMD Serono Inc; Consulting Agreements (Unpaid): Bavarian Nordic, Bristol-Myers Squibb Company, G1 Therapeutics Inc, QED Therapeutics, Seagen Inc; Travel Cost: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company; Writing/Editor Fees: Elsevier Practice Update Bladder Cancer Center of Excellence.

    Robert Svatek, MD
    Associate Professor
    Department of Urology
    UT Health Science Center
    San Antonio, Texas

    Consulting Agreement: Ferring Pharmaceuticals; Contracted Research: Japan BCG Laboratory, Rapamycin Holdings.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    These activities are supported by educational grants from Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

    Release date: December 2021
    Expiration date: December 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio
(WIFI is recommended for best performance):